İstanbul Sağlık ve Teknoloji Üniversitesi Kurumsal Akademik Arşivi
DSpace@İSTÜN, Üniversite mensupları tarafından doğrudan ve dolaylı olarak yayınlanan; kitap, makale, tez, bildiri, rapor, araştırma verisi gibi tüm akademik kaynakları uluslararası standartlarda dijital ortamda depolar, Üniversitenin akademik performansını izlemeye aracılık eder, kaynakları uzun süreli saklar ve telif haklarına uygun olarak Açık Erişime sunar.
Güncel Gönderiler
Investigation of volumetric alterations in thalamic subnuclei in progressive and stable mild cognitive impairment using magnetic resonance imaging
(İstanbul University Press, 2026) Harı, Emre; Soylu, Can
Objective: This study aimed to evaluate the volumes of thalamic subnuclei known to function in large-scale cognitive networks between progressive mild cognitive impairment (pMCI) and stable MCI (sMCI) groups progressing to dementia. Materials and Methods: Magnetic resonance imaging and clinical data of 31 pMCI (Age: 68.66±6.86; education: 15.71±2.46; gender: 15 female) and 31 sMCI (Age: 70.18±7.24; education: 16.23±2.68; gender: 13 female) patients with no statistically significant differences in age, gender, education, and follow-up interval (mean 21 months) from the Alzheimer's Disease Neuroimaging Initiative database were used. FreeSurfer software was used for individual thalamus segmentation and volume calculation. Thalamic nuclei were divided into anterior, medial, posterior, lateral, ventral, and intralaminar nucleus groups. The volumes of each nucleus were normalised using intracranial volume. Normalised volumes were compared between groups using independent samples t-test, and false discovery rate (FDR) correction was applied. Correlation analysis was performed using florbetapir (AV45) PET scores to evaluate the relationship between amyloid burden in the brain and volumetric decrease. Results: Statistically significant volumetric decreases were detected in the bilateral anterior (Right: t=2.432 pFDR=0.048; Left: t=2.327 pFDR=0.048) and lateral (t=2.372 pFDR=0.048) nucleus groups in pMCI compared to sMCI. A negative correlation was found between PET scores and bilateral anterior nucleus groups (Right: r=-0.353 p=0.026, left: r=-0.350 p=0.026). Conclusion: In our study, the anterior thalamic nucleus group, closely associated with memory, showed reduced volume in MCI patients who progressed to dementia, and this reduction correlated with amyloid burden in the brain. Based on the findings of our study, the anterior thalamic nucleus group may provide supportive value to other MRI biomarkers in predicting conversion to dementia.
A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF
(Elsevier, 2026) Hernandez Gea, Virginia; Paradis, Valerie; Guindi, Maha; Alves, Venancio A.F.; Aqul, Amal; Cerda, Eira; Darwish Murad, Sarwa; Das, Prasenjit; Örmeci, Necati; Rautou, Pierre Emmanuel
Noncirrhotic portal hypertension has historically been described using heterogeneous and region-specific terminology—such as idiopathic portal hypertension (IPH), noncirrhotic portal fibrosis (NCPF), obliterative portal venopathy, and nodular regenerative hyperplasia—leading to substantial variability in diagnosis, reporting, and international research collaboration. Differences in guideline definitions from major societies (AASLD, EASL, and APASL), together with the presence of characteristic histologic lesions in patients without clinically overt portal hypertension, have further complicated disease classification. To address these chal lenges, a large, multisociety, international initiative was convened to harmonize nomenclature and diagnos tic criteria. Representatives from liver, pathology, and pediatric hepatology societies across the Americas, Europe, and Asia participated in a structured consensus process that included specialized working groups and external Delphi validation. The initiative produced a globally harmonized and implementable diagnostic framework. Consensus was reached that the terms porto-sinusoidal vascular disorder (PSVD) and NCPF may be used interchangeably when identical diagnostic criteria are applied, and that they should be written as PSVD or NCPF. The diagnosis was defined as fundamentally clinicopathological, requiring integrated assess ment. Core principles include the need for a high-quality liver biopsy (≥ 10 mm), mandatory exclusion of cir rhosis, and systematic exclusion of specific alternative conditions. Importantly, the consensus recognizes that PSVD or NCPF may be diagnosed even without clinical portal hypertension and may coexist with other liver diseases, provided cirrhosis is excluded. Standard-ized major and minor histologic criteria were devel oped collaboratively by expert pathologists and externally validated. Features of portal hypertension were harmonized into specific and nonspecific categories applicable to routine clinical practice. An integrated diagnostic scoring system incorpo-rating histology, clinical features, associated conditions, and concommi tant etiologies was developed and validated using the Delphi method. This consensus provides the first inter nationally endorsed, unified framework for the diagnosis of PSVD or NCPF. Its global implementation is expected to reduce diagnostic variability, improve comparability across regions, and facilitate the develop ment of robust, internationally harmonized clinical and translational research cohorts.
A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF
(Elsevier, 2026) Hernandez Gea, Virginia; Paradis, Valerie; Guindi, Maha; Alves, Venancio A.F.; Aqul, Amal; Cerda, Eira; Darwish Murad, Sarwa; Das, Prasenjit; Örmeci, Necati; Rautou, Pierre Emmanuel
Non-cirrhotic portal hypertension has historically been described using heterogeneous and region-specific terminology, such as idiopathic portal hypertension (IPH), non-cirrhotic portal fibrosis (NCPF), obliterative portal venopathy, and nodular regenerative hyperplasia, leading to substantial variability in diagnosis, reporting, and international research collaboration. Differences in guideline definitions from major societies (AASLD, EASL, and APASL), together with the presence of characteristic histologic lesions in patients without clinically overt portal hypertension, have further complicated disease classification. To address these challenges, a large, multisociety, international initiative was convened to harmonize nomenclature and diagnostic criteria. Representatives from liver, pathology, and pediatric hepatology societies across the Americas, Europe, and Asia participated in a structured consensus process that included specialized working groups and external Delphi validation. The initiative produced a globally harmonized and implementable diagnostic framework. Consensus was reached that the terms porto-sinusoidal vascular disorder (PSVD) and NCPF may be used interchangeably when identical diagnostic criteria are applied, and that they should be written as PSVD or NCPF. The diagnosis was defined as fundamentally clinicopathological, requiring integrated assessment. Core principles include the need for a high-quality liver biopsy (> −10 mm), mandatory exclusion of cirrhosis, and systematic exclusion of specific alternative conditions. Importantly, the consensus recognizes that PSVD or NCPF may be diagnosed even without clinical portal hypertension and may coexist with other liver diseases, provided cirrhosis is excluded. Standardized major and minor histologic criteria were developed collaboratively by expert pathologists and externally validated. Features of portal hypertension were harmonized into specific and nonspecific categories applicable to routine clinical practice. An integrated diagnostic scoring system incorporating histology, clinical features, associated conditions, and concommitant etiologies was developed and validated using the Delphi method. This consensus provides the first internationally endorsed, unified framework for the diagnosis of PSVD or NCPF. Its global implementation is expected to reduce diagnostic variability, improve comparability across regions, and facilitate the development of robust, internationally harmonized clinical and translational research cohorts.
A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF
(Springer Nature Link, 2026) Hernandez Gea, Virginia; Paradis, Valerie; Guindi, Maha; Alves, Venancio A.F.; Aqul, Amal; Cerda, Eira; Darwish Murad, Sarwa; Das, Prasenjit; Örmeci, Necati; Rautou, Pierre Emmanuel
Noncirrhotic portal hypertension has historically been described using heterogeneous and region-specific terminology—such as idiopathic portal hypertension (IPH), noncirrhotic portal fibrosis (NCPF), obliterative portal venopathy, and nodular regenerative hyperplasia—leading to substantial variability in diagnosis, reporting, and international research collabora tion. Differences in guideline definitions from major societies (AASLD, EASL, and APASL), together with the presence of characteristic histologic lesions in patients without clinically overt portal hypertension, have further complicated disease classification. To address these challenges, a large, multisociety, international initiative was convened to harmonize nomen clature and diagnostic criteria. Representatives from liver, pathology, and pediatric hepatology societies across the Ameri cas, Europe, and Asia participated in a structured consensus process that included specialized working groups and external Delphi validation. The initiative produced a globally harmonized and implementable diagnostic framework. Consensus was reached that the terms porto–sinusoidal vascular disorder (PSVD) and NCPF may be used interchangeably when identical diagnostic criteria are applied, and that they should be written as PSVD or NCPF. The diagnosis was defined as fundamen tally clinicopathological, requiring integrated assessment. Core principles include the need for a high-quality liver biopsy (≥10 mm), mandatory exclusion of cirrhosis, and systematic exclusion of specific alternative conditions. Importantly, the consensus recognizes that PSVD or NCPF may be diagnosed even without clinical portal hypertension and may coexist with other liver diseases, provided cirrhosis is excluded. Standardized major and minor histologic criteria were developed col laboratively by expert pathologists and externally validated. Features of portal hypertension were harmonized into specific and nonspecific categories applicable to routine clinical practice. An integrated diagnostic scoring system incorporating histology, clinical features, associated conditions, and concommitant etiologies was developed and validated using the Delphi method. This consensus provides the first internationally endorsed, unified framework for the diagnosis of PSVD or NCPF. Its global implementation is expected to reduce diagnostic variability, improve comparability across regions, and facilitate the development of robust, internationally harmonized clinical and translational research cohorts.
The effect of different granulation amounts of kollicoat MAE 30DP® on ODT CQAs using risk assessment
(Marmara University, 2026) Pirinçci Tok, Yağmur; Demiralp, Burcu; Al-Mohaya, Mazen; Özsoy, Yıldız
Orally disintegrating tablets (ODTs) improve patient compliance, but they present challenges in terms of masking the bitter taste of active pharmaceutical ingredients such as dexketoprofen trometamol (DEX). The study aimed to develop palatable DEX ODTs by granulating drug with Kollicoat MAE 30DP® to create a physical barrier. Using a quality by design (QbD) approach, an initial risk assessment identified Prosolv® ODT G2, Emdex®, and Magnasweet® MM100 and tablet compression pressure as critical variables. A Box-Behnken design was employed to prepare 26 formulations, systematically evaluating the impact of these variables across low and high polymer concentrations. The results showed that although high concentrations of Kollicoat MAE 30DP initially delayed the dissolution rate, this barrier effect did not affect the final extent of drug release. Disintegration was predominantly governed by compression pressure, which altered tablet porosity, whereas PROSOLV® ODT G2 significantly influenced the overall dissolution profile. By optimizing the superdisintegrant-to-binder ratio, high-polymer formulations successfully overcame the initial retardation, consistently exceeding an 85% cumulative release at 30 minutes.
